Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis

Clinical Rheumatology

Volumn 34, Issue 10, 2015, Pages 1801-1805

  Bredemeier, Markus ^a   Campos, Guilherme G ^a   de Oliveira, Fernando K ^a  

^a HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

Author keywords

Arthritis rheumatoid; Dose response relationship drug; Meta analysis; Review systematic; Rituximab

Indexed keywords

IMMUNOGLOBULIN G; RITUXIMAB; ANTIRHEUMATIC AGENT; METHOTREXATE;

ARTICLE; ATTRIBUTABLE RISK; COMPARATIVE EFFECTIVENESS; DAS28; DISEASE ACTIVITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LOW DRUG DOSE; META ANALYSIS; MODIFIED TOTAL SHARP SCORE; MUSCULOSKELETAL DISEASE ASSESSMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION; IMMUNOLOGY; MIDDLE AGED; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOGLOBULIN G; METHOTREXATE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RITUXIMAB; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942294158     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-015-2977-z     Document Type: Article

References (18)

1. Bredemeier M, de Oliveira FK, Rocha CM (2014) Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 66:228–35. doi:10.1002/acr.22116
2. Vital EM, Md Yusof MY, Emery P (2014) Choosing the right rituximab dose for the right patient: comment on the article by Bredemeier et al. Arthritis Care Res (Hoboken) 66:1591–3. doi:10.1002/acr.22379
3. Bredemeier M (2014) Reply. Arthritis Care Res (Hoboken) 66:1593–6. doi:10.1002/acr.22382
4. Leandro MJ (2015) Rituximab and other B cell targeted therapies for rheumatoid arthritis. In: Romain PL, Maini RN (Eds), Uptodate, Waltham, MA. http://www.uptodate.com/contents/rituximab-and-other-b-cell-targeted-therapies-for-rheumatoid-arthritis. Accessed on 12 January 2015
5. Peterfy C, Emery P, Tak PP, Østergaard M, DiCarlo J, Otsa K et al (2014) MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Ann Rheum Dis. doi:10.1136/annrheumdis-2014-206015
6. Mariette X, Rouanet S, Sibilia J, Combe B, Le Loet X, Tebib J et al (2014) Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis 73:1508–14. doi:10.1136/annrheumdis-2013-203480
7. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. doi:10.1136/bmj.b2535
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–24
9. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al (1995) American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727–35
10. Batticciotto A, Varisco V, Antivalle M, Talotta R, Rigamonti F, Ventura D et al (2013) Dose reduction in patients with rheumatoid arthritis responding to the standard rituximab regimen. Ann Rheum Dis 72(Suppl):877
11. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, for the DANCER Study Group et al (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390–1400
12. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ et al (2010) Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 69:1629–35. doi:10.1136/ard.2009.119933
13. Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W et al (2012) Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis 71:351–7. doi:10.1136/annrheumdis-2011-200170
14. Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreno L, Armstrong G et al (2010) Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 49:1683–93. doi:10.1093/rheumatology/keq116
15. Bredemeier M (2012) Last observation carried forward approach threatens the validity of intent-to-treat analysis in fibromyalgia trials: comment on the article by Arnold et al. Arthritis Rheum 64:2809–10. doi:10.1002/art.34493
16. Leandro MJ, Becerra-Fernandez E (2011) B-cell therapies in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 25:535–48. doi:10.1016/j.berh.2011.10.005
17. Lydersen S (2015) Statistical review: frequently given comments. Ann Rheum Dis 74:323–5. doi:10.1136/annrheumdis-2014-206186
18. Ma Y, Mazumdar M, Memtsoudis SG (2012) Beyond repeated-measures analysis of variance: advanced statistical methods for the analysis of longitudinal data in anesthesia research. Reg Anesth Pain Méd 37:99–105. doi:10.1097/AAP.0b013e31823ebc74